Effects of Metformin in Experimental Stroke
Open Access
- 1 November 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Stroke
- Vol. 41 (11), 2645-2652
- https://doi.org/10.1161/strokeaha.110.589697
Abstract
Background and Purpose— Adenosine 5′-monophosphate-activated protein kinase (AMPK) is an important sensor of energy balance. Stroke-induced AMPK activation is deleterious because both pharmacological inhibition and genetic deletion of AMPK are neuroprotective. Metformin is a known AMPK activator but reduces stroke incidence in clinical populations. We investigated the effect of acute and chronic metformin treatment on infarct volume and AMPK activation in experimental stroke. Methods— Male mice were subjected to middle cerebral artery occlusion after acute (3 days) or chronic (3 weeks) administration of metformin. Infarct volumes, AMPK activation, lactate accumulation, and behavioral outcomes were assessed. The roles of neuronal nitric oxide synthase and AMPK were examined using mice with targeted deletion of AMPK or neuronal nitric oxide synthase. Results— Acute metformin exacerbated stroke damage, enhanced AMPK activation, and led to metabolic dysfunction. This effect was lost in AMPK and neuronal nitric oxide synthase knockout mice. In contrast, chronic metformin given prestroke was neuroprotective, improved stroke-induced lactate generation, and ameliorated stroke-induced activation of AMPK. Similarly, the neuroprotective effect of chronic prestroke metformin was lost in neuronal nitric oxide synthase knockout mice. Conclusions— AMPK is an important potential target for stroke treatment and prevention. These studies show that the timing, duration, and amount of AMPK activation are key factors in determining the ultimate downstream effects of AMPK on the ischemic brain.This publication has 32 references indexed in Scilit:
- Effects of AMP-Activated Protein Kinase in Cerebral IschemiaJournal of Cerebral Blood Flow & Metabolism, 2009
- Modification of Endothelial Nitric Oxide Synthase through AMPK after Experimental Subarachnoid HemorrhageJournal of Neurotrauma, 2009
- In Vivo Activation of AMP-Activated Protein Kinase Attenuates Diabetes-Enhanced Degradation of GTP Cyclohydrolase IDiabetes, 2009
- AMPK in the brain: its roles in energy balance and neuroprotectionJournal of Neurochemistry, 2009
- AMP-Activated Protein Kinase Functionally Phosphorylates Endothelial Nitric Oxide Synthase Ser633Circulation Research, 2009
- Contemporary risk factor control and walking dysfunction in individuals with peripheral arterial disease: NHANES 1999–2004Atherosclerosis, 2008
- Phosphorylation of LKB1 at Serine 428 by Protein Kinase C-ζ Is Required for Metformin-Enhanced Activation of the AMP-Activated Protein Kinase in Endothelial CellsCirculation, 2008
- AMP‐ACTIVATED PROTEIN KINASE ACTIVATION AS A STRATEGY FOR PROTECTING VASCULAR ENDOTHELIAL FUNCTIONClinical and Experimental Pharmacology and Physiology, 2007
- Neuroprotective Effects of Adenosine Monophosphate- Activated Protein Kinase Inhibition and Gene Deletion in StrokeStroke, 2007
- Role of AMP-activated protein kinase in mechanism of metformin actionJCI Insight, 2001